Results 201 to 210 of about 6,381,108 (341)
Bone metastasis in prostate cancer (PCa) patients is a clinical hurdle due to the poor understanding of the supportive bone microenvironment. Here, we identify stearoyl‐CoA desaturase (SCD) as a tumor‐promoting enzyme and potential therapeutic target in bone metastatic PCa.
Alexis Wilson +7 more
wiley +1 more source
Realization of a Family Systems Care Unit: A Real-Life Laboratory for Clinical Practice, Education, and Research at a Swiss University of Applied Sciences. [PDF]
Huber E +7 more
europepmc +1 more source
β‐TrCP overexpression enhances cisplatin sensitivity by depleting BRCA1
Low levels of β‐TrCP (Panel A) allow the accumulation of BRCA1 and CtIP, which facilitate the repair of cisplatin‐induced DNA damage via homologous recombination (HR) and promote tumor cell survival. In contrast, high β‐TrCP expression (Panel B) leads to BRCA1 and CtIP degradation, impairing HR repair, resulting in persistent DNA damage and apoptosis ...
Rocío Jiménez‐Guerrero +8 more
wiley +1 more source
Editorial: Mesenchymal stem cells and derived extracellular vesicles as next-generation biological drugs for tissue regeneration. [PDF]
Barbon S, Banerjee A, Porzionato A.
europepmc +1 more source
Natural Killer Cell Immune Checkpoints and Their Therapeutic Targeting in Cancer Treatment
Anqi Lin +7 more
openalex +1 more source
Therapeutic Effects of Nano-HAp in a Rat Model of AlCl3 Induced Neurotoxicity.
Osama Abbas +2 more
openalex +2 more sources
AZD9291 has shown promise in targeted cancer therapy but is limited by resistance. In this study, we employed metabolic labeling and LC–MS/MS to profile time‐resolved nascent protein perturbations, allowing dynamic tracking of drug‐responsive proteins. We demonstrated that increased NNMT expression is associated with drug resistance, highlighting NNMT ...
Zhanwu Hou +5 more
wiley +1 more source
Editorial: Overcoming resistance in DDR inhibition: new targets and therapeutic strategies. [PDF]
Tsai CL, Gonçalves AC, Ahmed Z.
europepmc +1 more source
EXPLORING BECLIN-1 THERAPEUTIC POTENTIAL IN NEURODEGENERATIVE DISEASES: FOCUS ON MULTIPLE SCLEROSIS
Arif Malik +8 more
openalex +2 more sources
PARP inhibitors are used to treat a small subset of prostate cancer patients. These studies reveal that PARP1 activity and expression are different between European American and African American prostate cancer tissue samples. Additionally, different PARP inhibitors cause unique and overlapping transcriptional changes, notably, p53 pathway upregulation.
Moriah L. Cunningham +21 more
wiley +1 more source

